Knockdown by shRNA identifies SLC44A5 as a potential therapeutic target in hepatocellular carcinoma

Peng,Gui‑Zhu; Ye,Qi‑Fa; Wang,Ren; Li,Ming‑Xia; Yang,Zi‑Xuan

doi:10.3892/mmr.2016.5136

Knockdown by shRNA identifies SLC44A5 as a potential therapeutic target in hepatocellular carcinoma

Authors:
- Gui‑Zhu Peng
- Qi‑Fa Ye
- Ren Wang
- Ming‑Xia Li
- Zi‑Xuan Yang
View Affiliations

Affiliations: Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan, Hubei 430071, P.R. China
Published online on: April 15, 2016 https://doi.org/10.3892/mmr.2016.5136
Pages: 4845-4852

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) has been ranked the second leading cause of cancer‑associated mortality in China and the third leading cause of cancer‑associated mortality worldwide. A number of previous studies investigating SLC44A5 have revealed important biological insight and disease‑specific functions. Therefore, the present study investigated the expression of SLC44A5 in HCC tissues and cell lines, and assessed the effect of SLC44A5 on the viability, cell cycle, apoptosis and invasion of HCC cell lines. The mRNA expression of SLC44A5 in 35 HCC tissues was significantly higher compared with that in 35 normal tissues. The protein expression of SLC44A5 was notably high in MHCC‑97H and SMMC‑7721 cells compared with that in four other HCC cell lines. Knockdown of SLC44A5 using short hairpin RNA inhibited cell viability and arrested the cells in G1 of the cell cycle by reducing the expression of cell cycle markers, proliferating cell nuclear antigen and cyclin‑dependent kinase 2 in MHCC‑97H and SMMC‑7721 cells. Furthermore, SLC44A5 knockdown cells also exhibited cell apoptosis by reducing the expression levels of apoptosis markers, caspase‑3 and caspase‑9 in MHCC‑97H and SMMC‑7721 cells, and suppressed invasion. The present results suggested that SLC44A5 is involved in HCC carcinogenesis and progression in HCC, indicating that SLC44A5 may be a molecular target in cancer therapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Lin ZZ, Shau WY, Hsu C, Shao YY, Yeh YC, Kuo RN, Hsu CH, Yang JC, Cheng AL and Lai MS: Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PloS One. 8:e802762013. View Article : Google Scholar : PubMed/NCBI
3	Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, Fleishman DI, Engelhardt NV and Duncan S: Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology. 39:1038–1047. 2004. View Article : Google Scholar : PubMed/NCBI
4	Hashiguchi M, Ueno S, Sakoda M, Iino S, Hiwatashi K, Minami K, Ando K, Mataki Y, Maemura K, Shinchi H, et al: Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC). BMC Cancer. 13:5722013. View Article : Google Scholar : PubMed/NCBI
5	Zeisel SH: Choline deficiency. J Nutr Biochem. 1:332–349. 1990. View Article : Google Scholar : PubMed/NCBI
6	Anderson OS, Sant KE and Dolinoy DC: Nutrition and epigenetics: An interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. J Nutr Biochem. 23:853–859. 2012. View Article : Google Scholar : PubMed/NCBI
7	Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S and Podo F: Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 65:9369–9376. 2005. View Article : Google Scholar : PubMed/NCBI
8	Michel V, Yuan Z, Ramsubir S and Bakovic M: Choline transport for phospholipid synthesis. Exp Biol Med (Maywood). 231:490–504. 2006.
9	O'Regan S, Traiffort E, Ruat M, Cha N, Compaore D and Meunier FM: An electric lobe suppressor for a yeast choline transport mutation belongs to a new family of transporter-like proteins. Proc Natl Acad Sci USA. 97:1835–1840. 2000. View Article : Google Scholar : PubMed/NCBI
10	Machová E, O'Regan S, Newcombe J, Meunier FM, Prentice J, Dove R, Lisá V and Dolezal V: Detection of choline transporter-like 1 protein CTL1 in neuroblastoma × glioma cells and in the CNS, and its role in choline uptake. J Neurochem. 110:1297–1309. 2009. View Article : Google Scholar
11	Kommareddi PK, Nair TS, Thang LV, Galano MM, Babu E, Ganapathy V, Kanazawa T, McHugh JB and Carey TE: Isoforms, expression, glycosylation and tissue distribution of CTL2/SLC44A2. Protein J. 29:417–426. 2010. View Article : Google Scholar : PubMed/NCBI
12	Traiffort E, Ruat M, O'Regan S and Meunier FM: Molecular characterization of the family of choline transporter-like proteins and their splice variants. J Neurochem. 92:1116–1125. 2005. View Article : Google Scholar : PubMed/NCBI
13	Shephard DA: The 1975 Declaration of Helsinki and consent. Can Med Assoc J. 115:1191–1192. 1976.PubMed/NCBI
14	Kunter I, Erdal E, Nart D, Yilmaz F, Karademir S, Sagol O and Atabey N: Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma. Oncol Rep. 31:573–580. 2014.
15	Hong X, Song R, Song H, Zheng T, Wang J, Liang Y, Qi S, Lu Z, Song X, Jiang H, et al: PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis. Gut. 63:1635–1647. 2014. View Article : Google Scholar
16	Inazu M: Choline transporter-like proteins CTLs/SLC44 family as a novel molecular target for cancer therapy. Biopharm Drug Dispos. 35:431–449. 2014. View Article : Google Scholar : PubMed/NCBI
17	Inazu M, Yamada T, Kubota N and Yamanaka T: Functional expression of choline transporter-like protein 1 (CTL1) in small cell lung carcinoma cells: A target molecule for lung cancer therapy. Pharmacol Res. 76:119–131. 2013. View Article : Google Scholar : PubMed/NCBI
18	Wang T, Li J, Chen F, Zhao Y, He X, Wan D and Gu J: Choline transporters in human lung adenocarcinoma: Expression and functional implications. Acta Bioch Bioph Sin (Shanghai). 39:668–674. 2007. View Article : Google Scholar
19	Awwad HM, Geisel J and Obeid R: The role of choline in prostate cancer. Clin Biochem. 45:1548–1553. 2012. View Article : Google Scholar : PubMed/NCBI
20	Kouji H, Inazu M, Yamada T, Tajima H, Aoki T and Matsumiya T: Molecular and functional characterization of choline transporter in human colon carcinoma HT-29 cells. Arch Biochem Biophys. 483:90–98. 2009. View Article : Google Scholar : PubMed/NCBI
21	Inazu M, Takeda H and Matsumiya T: Molecular and functional characterization of an Na+-independent choline transporter in rat astrocytes. J Neurochem. 94:1427–1437. 2005. View Article : Google Scholar : PubMed/NCBI
22	Yabuki M, Inazu M, Yamada T, Tajima H and Matsumiya T: Molecular and functional characterization of choline transporter in rat renal tubule epithelial NRK-52E cells. Arch Biochem Biophys. 485:88–96. 2009. View Article : Google Scholar : PubMed/NCBI
23	Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L, Zhou H and Zhao RC: miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol. 34:1461–1466. 2009.PubMed/NCBI
24	Sevli S, Uzumcu A, Solak M, Ittmann M and Ozen M: The function of microRNAs, small but potent molecules, in human prostate cancer. Prostate Cancer Prostatic Dis. 13:208–217. 2010. View Article : Google Scholar : PubMed/NCBI
25	Malumbres M and Barbacid M: Mammalian cyclin-dependent kinases. Trends Biochem Sci. 30:630–641. 2005. View Article : Google Scholar : PubMed/NCBI